J Neurol Surg A Cent Eur Neurosurg 2016; 77(05): 422-426
DOI: 10.1055/s-0036-1584212
Original Article
Georg Thieme Verlag KG Stuttgart · New York

Tranexamic Acid for Recurring Subdural Hematomas Following Surgical Evacuation: A Clinical Case Series

Joel M. Stary
1   Department of Neurosurgery, Virginia Commonwealth University Health System, Medical College of Virginia, Richmond, Virginia, United States
,
Leslie Hutchins
1   Department of Neurosurgery, Virginia Commonwealth University Health System, Medical College of Virginia, Richmond, Virginia, United States
,
Rafael A. Vega
1   Department of Neurosurgery, Virginia Commonwealth University Health System, Medical College of Virginia, Richmond, Virginia, United States
› Institutsangaben
Weitere Informationen

Publikationsverlauf

04. Oktober 2015

24. März 2016

Publikationsdatum:
14. Juni 2016 (online)

Preview

Abstract

Background Chronic subdural hematomas (SDHs) are commonly encountered in neurosurgery. Optimal management of SDHs remains a significant challenge. Current treatment options generally include supportive care or surgical intervention. A significant proportion of patients have surgery; however, the reoperation rate is considered high. There are also cases in which additional surgical procedures would carry significant morbidity, and as a result, there is a need for nonsurgical medical therapies. We describe the use of tranexamic acid (TXA) as a nonsurgical option for the treatment of recurrent SDHs following surgery.

Methods Patients were identified as candidates for potential TXA therapy and followed prospectively. The decision to administer TXA was made on the basis of history, presentation, and prognosis after further surgical intervention. Data collected included patient imaging, treatment administered, and both radiologic and clinical outcomes.

Results Three patients underwent surgical evacuation of a chronic SDH (two via burr hole washout and one via craniotomy). All patients had recurrence identified on subsequent imaging. Two patients had poorer predicted outcomes if additional surgical intervention was necessary, and one refused additional surgical intervention. TXA was administered, in the same dosing and scheduled course, to all patients. Complete resolution was observed on imaging, and in the case of the patient who was symptomatic, clinical improvement was also noted.

Conclusion TXA may be considered for the treatment of recurrent SDHs following surgical evacuation in patients for whom additional surgery would add significant morbidity.